9.16 0.00 (0.04%)
After hours: 4:10PM EDT
|Bid||9.00 x 500|
|Ask||9.70 x 200|
|Day's Range||9.02 - 9.46|
|52 Week Range||1.17 - 11.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $12,000 in the period. For the year, the company reported ...
Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.
Categories: Yahoo FinanceGet free summary analysis Endocyte, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Endocyte, Inc. – Madrigal Pharmaceuticals, Inc., Nektar Therapeutics and Verastem, Inc. (MDGL-US, NKTR-US and VSTM-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.03 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Endocyte, Inc. Here are 5 ETFs with the largest exposure to ECYT-US. Comparing the performance and risk of Endocyte, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The West Lafayette, Indiana-based company said it had a loss of 55 cents per share. Losses, adjusted for costs related to mergers and acquisitions, were 30 cents per share. The biopharmaceutical company ...
Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.